{
  "success": true,
  "pagesUsed": [
    3,
    4,
    5,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of Drug X compared to placebo",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Objective",
        "text": "To characterize the overall survival benefit",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety Objective",
        "text": "To evaluate safety and tolerability of PDR001 in combination with dabrafenib and trametinib",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Biomarker Objective",
        "text": "To identify and characterize potential resistance mechanism",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "investigator-assessed PFS",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary Endpoint",
        "text": "Overall Survival (OS)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Safety Endpoint",
        "text": "Incidence and severity of adverse events (AEs) and treatment related AEs (TRAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_4",
        "name": "Exploratory Biomarker Endpoint",
        "text": "Mandatory blood and optional tissue sample collection at the time of progression",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - PFS",
        "populationSummary": "Adult patients with untreated BRAF V600 mutant melanoma (Full Analysis Set/ITT) Summary measure: Hazard Ratio (HR) from a stratified Cox proportional hazards model.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment for any reason other than disease progression or death",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to any cause",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "COVID-19 related disruption",
            "text": "Delays in treatment or virtual visits due to the COVID-19 pandemic",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "PDR001 in combination with dabrafenib and trametinib vs Placebo in combination with dabrafenib and trametinib",
        "analysisPopulation": "Adult patients with untreated BRAF V600 mutant melanoma (Full Analysis Set/ITT)",
        "variableOfInterest": "Progression-Free Survival (PFS) based on investigator assessment per RECIST 1.1",
        "summaryMeasure": "Hazard Ratio (HR) from a stratified Cox proportional hazards model"
      },
      {
        "id": "est_2",
        "name": "Key Secondary Estimand - OS",
        "populationSummary": "Adult patients with untreated BRAF V600 mutant melanoma (Full Analysis Set/ITT) Summary measure: Hazard Ratio (HR).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment switching/Unblinding",
            "text": "Mandatory unblinding and discontinuation of placebo following final PFS analysis",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "PDR001 in combination with dabrafenib and trametinib vs Placebo in combination with dabrafenib and trametinib",
        "analysisPopulation": "Adult patients with untreated BRAF V600 mutant melanoma (Full Analysis Set/ITT)",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio (HR)"
      },
      {
        "id": "est_3",
        "name": "Safety Estimand",
        "populationSummary": "All patients who received at least one dose of study treatment (Safety Set) Summary measure: Risk difference or frequency proportions.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of any or all three drugs due to AEs",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "PDR001 in combination with dabrafenib and trametinib vs Placebo in combination with dabrafenib and trametinib",
        "analysisPopulation": "All patients who received at least one dose of study treatment (Safety Set)",
        "variableOfInterest": "Incidence and severity of adverse events (AEs) and treatment related AEs (TRAEs)",
        "summaryMeasure": "Risk difference or frequency proportions"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 2,
      "exploratoryObjectives": 1,
      "totalEndpoints": 4,
      "totalEstimands": 3
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To evaluate the efficacy of Drug X compared to placebo",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Key Secondary Objective",
        "text": "To characterize the overall survival benefit",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Safety Objective",
        "text": "To evaluate safety and tolerability of PDR001 in combination with dabrafenib and trametinib",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Biomarker Objective",
        "text": "To identify and characterize potential resistance mechanism",
        "level": {
          "code": "C163559",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Exploratory Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary Efficacy Endpoint",
        "text": "investigator-assessed PFS",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Key Secondary Endpoint",
        "text": "Overall Survival (OS)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Safety Endpoint",
        "text": "Incidence and severity of adverse events (AEs) and treatment related AEs (TRAEs)",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_4",
        "name": "Exploratory Biomarker Endpoint",
        "text": "Mandatory blood and optional tissue sample collection at the time of progression",
        "level": {
          "code": "C98724",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Exploratory Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary Efficacy Estimand - PFS",
        "populationSummary": "Adult patients with untreated BRAF V600 mutant melanoma (Full Analysis Set/ITT) Summary measure: Hazard Ratio (HR) from a stratified Cox proportional hazards model.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment for any reason other than disease progression or death",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to any cause",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "COVID-19 related disruption",
            "text": "Delays in treatment or virtual visits due to the COVID-19 pandemic",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "PDR001 in combination with dabrafenib and trametinib vs Placebo in combination with dabrafenib and trametinib",
        "analysisPopulation": "Adult patients with untreated BRAF V600 mutant melanoma (Full Analysis Set/ITT)",
        "variableOfInterest": "Progression-Free Survival (PFS) based on investigator assessment per RECIST 1.1",
        "summaryMeasure": "Hazard Ratio (HR) from a stratified Cox proportional hazards model"
      },
      {
        "id": "est_2",
        "name": "Key Secondary Estimand - OS",
        "populationSummary": "Adult patients with untreated BRAF V600 mutant melanoma (Full Analysis Set/ITT) Summary measure: Hazard Ratio (HR).",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment switching/Unblinding",
            "text": "Mandatory unblinding and discontinuation of placebo following final PFS analysis",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "PDR001 in combination with dabrafenib and trametinib vs Placebo in combination with dabrafenib and trametinib",
        "analysisPopulation": "Adult patients with untreated BRAF V600 mutant melanoma (Full Analysis Set/ITT)",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio (HR)"
      },
      {
        "id": "est_3",
        "name": "Safety Estimand",
        "populationSummary": "All patients who received at least one dose of study treatment (Safety Set) Summary measure: Risk difference or frequency proportions.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of any or all three drugs due to AEs",
            "strategy": "While on Treatment",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "PDR001 in combination with dabrafenib and trametinib vs Placebo in combination with dabrafenib and trametinib",
        "analysisPopulation": "All patients who received at least one dose of study treatment (Safety Set)",
        "variableOfInterest": "Incidence and severity of adverse events (AEs) and treatment related AEs (TRAEs)",
        "summaryMeasure": "Risk difference or frequency proportions"
      }
    ]
  }
}